Literature DB >> 17904305

The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer.

John M Robertson1, David Lockman, Di Yan, Michelle Wallace.   

Abstract

PURPOSE: Previous work has found a highly significant relationship between the irradiated small-bowel volume and development of Grade 3 small-bowel toxicity in patients with rectal cancer. This study tested the previously defined parameters in a much larger group of patients. METHODS AND MATERIALS: A total of 96 consecutive patients receiving pelvic radiation therapy for rectal cancer had treatment planning computed tomographic scans with small-bowel contrast that allowed the small bowel to be outlined with calculation of a small-bowel dose-volume histogram for the initial intended pelvic treatment to 45 Gy. Patients with at least one parameter above the previously determined dose-volume parameters were considered high risk, whereas those with all parameters below these levels were low risk. The grade of diarrhea and presence of liquid stool was determined prospectively.
RESULTS: There was a highly significant association with small-bowel dose-volume and Grade 3 diarrhea (p < or = 0.008). The high-risk and low-risk parameters were predictive with Grade 3 diarrhea in 16 of 51 high-risk patients and in 4 of 45 low-risk patients (p = 0.01). Patients who had undergone irradiation preoperatively had a lower incidence of Grade 3 diarrhea than those treated postoperatively (18% vs. 28%; p = 0.31); however, the predictive ability of the high-risk/low-risk parameters was better for preoperatively (p = 0.03) than for postoperatively treated patients (p = 0.15). Revised risk parameters were derived that improved the overall predictive ability (p = 0.004).
CONCLUSIONS: The highly significant dose-volume relationship and validity of the high-risk and low-risk parameters were confirmed in a large group of patients. The risk parameters provided better modeling for the preoperative patients than for the postoperative patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904305     DOI: 10.1016/j.ijrobp.2007.06.066

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  38 in total

1.  A treatment planning study of prone vs. supine positions for locally advanced rectal carcinoma : Comparison of 3‑dimensional conformal radiotherapy, tomotherapy, volumetric modulated arc therapy, and intensity-modulated radiotherapy.

Authors:  Sergiu Scobioala; Christopher Kittel; Philipp Niermann; Heidi Wolters; Katharina Helene Susek; Uwe Haverkamp; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2018-05-31       Impact factor: 3.621

Review 2.  Therapeutic approaches in the management of locally advanced rectal cancer.

Authors:  Simon D Fung-Kee-Fung
Journal:  J Gastrointest Oncol       Date:  2014-10

Review 3.  Current treatment of rectal cancer adapted to the individual patient.

Authors:  Laura Cerezo; Juan Pablo Ciria; Leire Arbea; Olga Liñán; Sergio Cafiero; Vincenzo Valentini; Francesco Cellini
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-03

4.  Small bowel toxicity after high dose spot scanning-based proton beam therapy for paraspinal/retroperitoneal neoplasms.

Authors:  R A Schneider; V Vitolo; F Albertini; T Koch; C Ares; A Lomax; G Goitein; E B Hug
Journal:  Strahlenther Onkol       Date:  2013-09-21       Impact factor: 3.621

Review 5.  Colon Cancer: Inflammation-Associated Cancer.

Authors:  Sherief Shawki; Jean Ashburn; Steven A Signs; Emina Huang
Journal:  Surg Oncol Clin N Am       Date:  2017-12-15       Impact factor: 3.495

6.  Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer.

Authors:  T Jonathan Yang; Jung Hun Oh; Christina H Son; Aditya Apte; Joseph O Deasy; Abraham Wu; Karyn A Goodman
Journal:  Gastrointest Cancer Res       Date:  2013-09

7.  Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer.

Authors:  Arti Parekh; Minh Tam Truong; Itai Pashtan; Muhammad M Qureshi; Neil E Martin; Omer Nawaz; Sandra Cerda; John Willins; Kevan L Hartshorn; Lisa A Kachnic
Journal:  Gastrointest Cancer Res       Date:  2013-09

8.  Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1.

Authors:  Lindsay C Brown; Pamela J Atherton; Michelle A Neben-Wittich; Donald B Wender; Robert J Behrens; Timothy F Kozelsky; Charles L Loprinzi; Michael G Haddock; James A Martenson
Journal:  Support Care Cancer       Date:  2013-06-08       Impact factor: 3.603

9.  Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience.

Authors:  Antonella Richetti; Antonella Fogliata; Alessandro Clivio; Giorgia Nicolini; Gianfranco Pesce; Emanuela Salati; Eugenio Vanetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2010-02-19       Impact factor: 3.481

10.  Pelvic Ewing sarcomas. Three-dimensional conformal vs. intensity-modulated radiotherapy.

Authors:  F S Mounessi; P Lehrich; U Haverkamp; N Willich; T Bölling; H T Eich
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.